Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
This study is ongoing, but not recruiting participants.
Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute
Emory University
University of North Carolina, Chapel Hill
Genentech
OSI Pharmaceuticals
Information provided by (Responsible Party):
Lori J. Wirth, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00392665
First received: October 24, 2006
Last updated: March 6, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |